Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Alkem Laboratories
Join Channel
Consolidated Standalone

Alkem Laboratories

₹5210.5 84.8 | 1.7%

Market Cap ₹62299 Cr.

Stock P/E 39.6

P/B 6

Current Price ₹5210.5

Book Value ₹ 873.7

Face Value 2

52W High ₹5519.1

Dividend Yield 0.96%

52W Low ₹ 3211.1

Edit Ratio

Alkem Laboratories Research see more...

Overview Inc. Year: 1973Industry: Pharmaceuticals & Drugs

Alkem Laboratories Limited is a pharmaceutical agency. The Company is engaged inside the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates via 2 segments: pharmaceutical and investing. The Company produces generics,generic drugs, APIs and neutraceuticals, which it markets in India and about 50 international locations across the world. The Company offers numerous products, which include CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, amongst others. The Company has approximately 16 production facilities, of which 14 manufacturing facilities are at geographically different places in India and within the United States.

Read More..

Alkem Laboratories Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Alkem Laboratories Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 2800 2619 2484 2576 3079 3041 2903 2968 3440 3324
Other Income 42 54 21 51 51 45 69 66 63 94
Total Income 2842 2673 2504 2628 3130 3086 2971 3034 3503 3418
Total Expenditure 2176 2121 2147 2373 2625 2442 2549 2579 2693 2616
Operating Profit 666 552 358 255 505 644 422 455 810 801
Interest 12 11 17 27 25 27 29 30 30 25
Depreciation 73 77 83 76 77 78 78 72 74 70
Exceptional Income / Expenses 0 0 -15 0 0 0 -103 0 -58 -51
Profit Before Tax 582 464 243 152 402 539 212 353 648 655
Provision for Tax 23 -69 134 20 55 79 144 65 33 51
Profit After Tax 559 533 108 131 348 460 68 288 615 604
Adjustments -14 -8 -1 -4 -17 -5 3 -1 6 -9
Profit After Adjustments 544 526 108 128 331 455 71 287 621 595
Adjusted Earnings Per Share 45.5 44 9 10.7 27.7 38 5.9 24 51.9 49.8

Alkem Laboratories Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 2495 3126 3743 4925 5688 6392 7357 8344 8865 10634 11599 12635
Other Income 167 165 181 240 112 115 88 104 233 163 216 292
Total Income 2662 3291 3924 5165 5800 6507 7445 8449 9098 10797 11815 12926
Total Expenditure 2133 2716 3322 4072 4689 5383 6242 6871 6923 8581 9990 10437
Operating Profit 530 575 603 1093 1111 1124 1202 1578 2176 2216 1826 2488
Interest 88 93 81 71 45 55 55 65 59 52 107 114
Depreciation 40 52 71 93 101 143 193 253 275 304 310 294
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 -15 -103 -212
Profit Before Tax 402 430 451 928 965 926 955 1260 1842 1844 1305 1868
Provision for Tax 18 -5 59 176 60 288 181 110 224 164 298 293
Profit After Tax 384 435 392 752 905 638 774 1149 1618 1680 1007 1575
Adjustments 0 0 0 -11 -13 -7 -13 -22 -33 -35 -23 -1
Profit After Adjustments 384 435 392 742 892 631 761 1127 1585 1646 984 1574
Adjusted Earnings Per Share 32.1 36.4 32.8 62 74.6 52.8 63.6 94.3 132.6 137.7 82.3 131.6

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 9% 12% 13% 17%
Operating Profit CAGR -18% 5% 10% 13%
PAT CAGR -40% -4% 10% 10%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 52% 20% 25% NA%
ROE Average 11% 19% 18% 18%
ROCE Average 13% 18% 18% 18%

Alkem Laboratories Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 2177 2585 2999 3692 4468 4864 5439 6161 7377 8638 9045
Minority's Interest 0 0 86 95 115 122 133 148 181 209 390
Borrowings 256 232 33 123 182 131 231 74 28 9 0
Other Non-Current Liabilities 106 92 167 -430 -582 -489 -520 -614 -779 -902 -688
Total Current Liabilities 1732 1403 2006 1538 1690 2383 2218 3245 3604 4805 3707
Total Liabilities 4271 4311 5291 5018 5872 7010 7501 9013 10411 12760 12454
Fixed Assets 1072 1170 1374 1450 1797 2284 2530 2908 2793 2902 2683
Other Non-Current Assets 1042 1539 1579 800 1158 713 754 599 690 1423 1042
Total Current Assets 2156 1602 2338 2769 2915 4013 4204 5488 6923 8434 8606
Total Assets 4271 4311 5291 5018 5872 7010 7501 9013 10411 12760 12454

Alkem Laboratories Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 26 57 101 124 127 167 167 249 176 174 232
Cash Flow from Operating Activities 78 290 325 726 471 266 780 585 1265 1111 1683
Cash Flow from Investing Activities -404 350 -237 202 -286 -357 -316 -741 -999 -1435 113
Cash Flow from Financing Activities 356 -600 -52 -927 -138 85 -379 79 -272 380 -1761
Net Cash Inflow / Outflow 30 41 37 1 47 -7 84 -77 -5 55 35
Closing Cash & Cash Equivalent 57 101 140 127 167 167 249 176 174 232 274

Alkem Laboratories Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 32.09 36.4 32.76 62.03 74.62 52.78 63.61 94.28 132.58 137.65 82.32
CEPS(Rs) 35.4 40.77 38.69 70.73 84.14 65.37 80.87 117.28 158.29 165.98 110.18
DPS(Rs) 4 4 4 12.7 15 13 16 25 30 34 50
Book NAV/Share(Rs) 182.05 216.13 250.86 308.82 373.67 406.76 454.86 515.21 616.95 722.48 756.56
Core EBITDA Margin(%) 14.07 12.66 10.93 16.9 17.07 11.76 10.41 11.89 14.82 13.44 8.97
EBIT Margin(%) 19.02 16.15 13.78 19.8 17.25 11.43 9.42 10.69 14.5 12.42 7.87
Pre Tax Margin(%) 15.59 13.28 11.68 18.39 16.48 10.79 8.91 10.16 14.05 12.07 7.27
PAT Margin (%) 14.9 13.44 10.15 14.9 15.46 7.44 7.22 9.27 12.34 11 5.61
Cash Profit Margin (%) 16.44 15.06 11.98 16.75 17.19 9.1 9.03 11.31 14.43 12.99 7.34
ROA(%) 9.92 10.14 8.16 14.59 16.61 9.91 10.66 13.92 16.66 14.5 7.99
ROE(%) 19.19 18.28 14.03 22.48 22.18 13.69 15.02 19.82 23.91 20.99 11.39
ROCE(%) 14.96 14.06 13.27 23.1 21.31 17.86 16.49 18.71 22.56 18.69 13.09
Receivable days 40.02 38.62 42.27 39.57 39.95 38.15 39.69 42.66 45.33 41.72 40.86
Inventory Days 66.53 66.19 66.41 61.23 65.96 56.31 50.14 48.86 57.51 63.54 57.1
Payable days 118.68 92.7 96.89 117.1 133.45 156.37 135.69 118.18 118.18 114.79 97.4
PER(x) 0 0 0 22.03 29.58 37.46 27.54 24.7 20.91 26.28 41.27
Price/Book(x) 0 0 0 4.42 5.91 4.86 3.85 4.52 4.49 5.01 4.49
Dividend Yield(%) 0 0 0 0.93 0.68 0.66 0.91 1.07 1.08 0.94 1.47
EV/Net Sales(x) 0.23 0.3 0.14 3.29 4.68 3.76 2.88 3.4 3.71 4.07 3.39
EV/Core EBITDA(x) 1.07 1.62 0.89 14.83 23.98 21.4 17.65 17.98 15.1 19.52 21.53
Net Sales Growth(%) 23.79 25.28 19.75 31.56 15.49 12.38 15.1 13.42 6.24 19.96 9.08
EBIT Growth(%) -0.33 6.78 1.7 87.93 1.01 -2.82 2.85 31.27 43.49 -0.23 -25.55
PAT Growth(%) -5.47 13.47 -10.05 92.1 20.27 -29.43 21.18 48.56 40.76 3.87 -40.08
EPS Growth(%) -5.59 13.42 -10.01 89.38 20.29 -29.27 20.54 48.2 40.63 3.82 -40.19
Debt/Equity(x) 0.71 0.44 0.44 0.18 0.15 0.21 0.17 0.26 0.23 0.3 0.14
Current Ratio(x) 1.25 1.14 1.17 1.8 1.73 1.68 1.9 1.69 1.92 1.76 2.32
Quick Ratio(x) 0.93 0.7 0.77 1.21 1.01 1.08 1.22 1.13 1.28 1.13 1.62
Interest Cover(x) 5.55 5.62 6.56 14.03 22.36 17.74 18.48 20.36 32.26 36.22 13.15
Total Debt/Mcap(x) 0 0 0 0.04 0.02 0.04 0.05 0.06 0.05 0.06 0.03

Alkem Laboratories Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 57.13 57.13 57.14 57.16 57.16 57.16 57.16 56.74 56.74 56.74
FII 5.4 5.41 5.67 4.46 4.41 4.44 5.64 6.03 8.49 9.11
DII 13.94 14.14 14.1 15.74 16.44 16.69 16.34 17.64 15.91 15.63
Public 23.53 23.32 23.09 22.65 21.99 21.7 20.86 19.59 18.86 18.52
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 114.79 to 97.4days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 6 times its book value.
  • The company has delivered a poor profit growth of 9% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Alkem Laboratories News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!